PDT+triamcinolone acetonide = reduced re-treatments

Article

Using photodynamic therapy (PDT) and high-dose intravitreal triamcinolone to treat neovascular age-related macular degeneration (AMD) associated with choroidal neovascularization (CNV) stabilizes vision and reduces the need for re-treatments, according to the results of a study published in the April/May issue of Retina Journal.

Using photodynamic therapy (PDT) and high-dose intravitreal triamcinolone to treat neovascular age-related macular degeneration (AMD) associated with choroidal neovascularization (CNV) stabilizes vision and reduces the need for re-treatments, according to the results of a study published in the April/May issue of Retina Journal.

Jose Ruiz-Moreno and colleagues from the Miguel Hernández University School of Medicine, Alicante, Spain conducted a prospective, consecutive, comparative, non-randomized interventional case series of 30 patients (30 eyes) with subfoveal CNV associated with AMD. Each subject was treated with PDT followed by an intravitreal injection of 19.4±2.1 mg triamcinolone acetonide. Fifteen eyes were naïve to treatment (group 1) while 15 had previously been treated with PDT alone (group 2). Fifteen patients treated with PDT alone served as the control group.

By the two-year follow-up, best corrected visual acuity (BCVA) had not changed significantly in group 1 (0.0±3.4; p=0.81); group 2 had lost and average of -0.6±2.5 lines (p=0.41) and the control group had lost an average of -2.2±3.4 lines. The mean number of PDT sessions during the 24-month follow-up was 1.9, 1.2 and 3.9 for group 1, group 2 and the control group, respectively.

The authors believe that PDT combined with high-dose intravitreal trimacinolone acetonide can help stabilize BCVA and reduce the need for re-treatments.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.